Search results for " Staging"

showing 10 items of 717 documents

Implication of the Examining Pathologist to Meet the Oncologic Standard of Lymph Node Count after Laparoscopic Lymphadenectomy

2010

<i>Objective:</i> The lymph node number as benchmark in oncologic operations depends on the patient’s anatomy, surgeon’s skill and pathologist’s accuracy. The influence of the pathologist is barely evaluated. <i>Methods:</i> A retrospective analysis of lymph node numbers after 700 laparoscopic lymphadenectomies in correlation to the examining pathologists was done. Three surgeons from the same department performed all operations at 2 campi, where 2 separate pathology institutions exist. Lymph node specimens were assigned randomly to any of the 62 involved pathologists. <i>Results:</i> The mean number of lymph nodes was equal for all surgeons. Lymph node s…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAdolescentPelviPathology Surgicalmedicine.medical_treatmentGynecologic oncologyMedical OncologyPelvisYoung AdultRetrospective StudieGynecologic oncology; Laparoscopic lymphadenectomy; Lymph node numberNeoplasmsHumansMedicineLaparoscopyLaparoscopic lymphadenectomyLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overLaparoscopic lymphadenectomymedicine.diagnostic_testbusiness.industryGeneral surgeryLymph NodeGeneral MedicineMiddle AgedSettore MED/40 - Ginecologia E Ostetriciadigestive system diseasesEndoscopyGynecologic oncologysurgical procedures operativemedicine.anatomical_structureOncologyLymph node numberPractice Guidelines as TopicNeoplasmLymph Node ExcisionFemaleLaparoscopyLymphadenectomyLymph NodesbusinessHumanOncology
researchProduct

Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

2010

Purpose To assess response of locally advanced rectal carcinoma to chemoradiation with regard to mucinous status and local tumor invasion found at pretherapeutic magnetic resonance imaging (MRI). Methods and Materials A total of 88 patients were included in this prospective study of patients with advanced mrT3 and mrT4 carcinomas. Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous. Patients received neoadjuvant chemoradiation consisting of 50.4 Gy (1.8 Gy/fraction) and 5-fluorouracil on Days 1 to 5 and Days 29 to 33. Therapy response was assessed by comparing pretherapeutic MRI with histopathology of surgical specimens (minimum…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyAntimetabolites AntineoplasticNeoplasm ResidualColorectal cancerRectumDrug Administration SchedulemedicineMucinous carcinomaHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overRadiationmedicine.diagnostic_testbusiness.industryRectal NeoplasmsCarcinomaDose fractionationMagnetic resonance imagingChemoradiotherapyMiddle Agedmedicine.diseaseAdenocarcinoma MucinousMagnetic Resonance ImagingNeoadjuvant TherapyTumor Burdenmedicine.anatomical_structureTreatment OutcomeOncologyAdenocarcinomaHistopathologyFemaleRadiologyDose Fractionation RadiationFluorouracilbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.

1997

BACKGROUND. Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS. In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS. Light microscopic study sh…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyEsophageal NeoplasmsApoptosisEpitheliumDiagnosis DifferentialCytokeratinNecrosisSex FactorsCarcinoma BasosquamousmedicineCarcinomaHumansNeoplasm InvasivenessEsophagusBasaloid Squamous Cell CarcinomaAgedNeoplasm StagingAged 80 and overMucous Membranebusiness.industryCarcinoma in situS100 ProteinsAge FactorsCell DifferentiationMiddle Agedmedicine.diseasePrognosisAntigens DifferentiationImmunohistochemistryActinsSurvival Ratestomatognathic diseasesMicroscopy Electronmedicine.anatomical_structureOncologyEpidermoid carcinomaDysplasiaCarcinoma Squamous CellKeratinsHistopathologyFemalebusinessCarcinoma in SituCell DivisionCancer
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases.

2000

BACKGROUND. The early detection and treatment of tumor recurrences in melanoma patients is dependent on reliable, sensitive, and specific techniques to verify suspected tumor metastases. As of now, fine-needle aspiration cytology (FNAC) has yet to establish itself in the routine follow-up of melanoma patients. METHODS. FNAC procedures were performed in melanoma patients with palpable tumors or nonpalpable, ultrasonically suspicious lesions. Cytodiagnostic evaluation of fine-needle samples obtained from suspicious lesions was performed morphologically. Findings were validated either by histopathologic diagnosis or prolonged clinical follow-up. RESULTS. The cytologic examination of 739 FNACs …

AdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsAdolescentEarly detectionSensitivity and SpecificityMetastasisFine needle aspiration cytologyCytologyBiopsymedicineHumansSampling (medicine)Neoplasm MetastasisMelanomaUltrasonography InterventionalAgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryMelanomaUltrasoundBiopsy NeedleReproducibility of ResultsMiddle Agedmedicine.diseasebody regionsOncologyFemaleRadiologybusinessCancer
researchProduct

Primary cutaneous melanoma in hidden sites is associated with thicker tumours — a study of 829 patients

2001

The aim of this study was to determine if primary cutaneous melanomas in hidden anatomical sites were associated with thicker tumours. Retrospective medical data of 829 patients with melanomas diagnosed at our centre between January 1976 and July 1998 were recorded from our database. Three groups were defined according to the anatomical site of the primary melanoma: (1) visible areas (group 1: 493 patients); (2) visible areas only to the patients or to their partners in privacy (group 2: 281 patients); and (3) hidden areas (group 3: 55 patients). Univariate analysis indicated that patients with melanoma in hidden regions presented significantly thicker tumours (median for group 3: 2.25 vers…

AdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsMultivariate analysisAdolescentDiseaseBreslow ThicknessSex FactorsInternal medicinemedicineHumansMelanomaAgedNeoplasm StagingRetrospective StudiesAged 80 and overAnalysis of VarianceUnivariate analysisbusiness.industryMelanomaAge FactorsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryAnatomical sitesOncologyCutaneous melanomaFemalebusinessEuropean Journal of Cancer
researchProduct

Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lym…

2011

Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), i.e. CPOP (cyclophosphamide, pixantrone, vincristine, and prednisone), in patients with relapsed aNHL who had previously received CHOP ± rituximab. Patients were administered pixantrone on day 1 of each 21-day cycle. Phase I (n = 35) dose escalation from 80 mg/m(2) to 180 mg/m(2) established the phase II (n = 30) dose as 150 mg/m(2). In phase II, 20 patients (67%) received all…

AdultMaleCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidePhases of clinical researchAntineoplastic AgentsPharmacologyGastroenterologychemistry.chemical_compoundPrednisoneRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedNeoplasm StagingAged 80 and overPixantronebusiness.industryLymphoma Non-HodgkinHematologyMiddle Agedmedicine.diseaseIsoquinolinesSurvival AnalysisTreatment OutcomeOncologychemistryVincristinePrednisoneMantle cell lymphomaFemalebusinessDiffuse large B-cell lymphomaFebrile neutropeniaImmunosuppressive Agentsmedicine.drugLeukemialymphoma
researchProduct

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in…

2005

An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m(-2), LV 500 mg m(-2), 24-h 5-FU 2000 mg m(-2), and ELF comprised three once-daily doses of etoposide 120 mg m(-2), LV 300 mg m(-2), 5-FU 500 mg m(-2). In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classLeucovorinPhases of clinical researchNeutropeniaAdenocarcinomaIrinotecanAntimetaboliteGastroenterologygastricStomach NeoplasmsInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans5-fluorouracilStomach cancerEtoposidePeritoneal NeoplasmsAgedEtoposideNeoplasm StagingLevoleucovorinbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgerymetastaticIrinotecanELFTreatment OutcomeOncologyTolerabilityFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilbusinessILFmedicine.drugBritish Journal of Cancer
researchProduct

p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or again…

2000

The aim of this study was to determine whether p53 is helpful in making the decision to undergo cystectomy in T1, G3 transitional cell carcinoma (TCC) of the bladder, by prospectively comparing the p53 status of bladder biopsies with the histology and p53 status of the corresponding cystectomy specimens. From January 1996 to August 1997, 38 consecutive patients with T1G3 TCC at 6 different centres were enrolled into the study. Bladder biopsies and cystectomy specimens were examined with three different antibodies against p53. The p53 status of each bladder biopsy was compared with p53 status, tumour stage and grade of the cystectomy specimen. An independent evaluation of the histology and i…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBiopsyUrinary BladderUrologyCystectomyCystectomyBiopsymedicineHumansProspective StudiesAgedNeoplasm StagingCarcinoma Transitional CellBladder cancerUrinary bladdermedicine.diagnostic_testbusiness.industryHistologyMiddle Agedmedicine.diseaseImmunohistochemistrySurgeryTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsImmunohistochemistryHistopathologyFemaleTumor Suppressor Protein p53businessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct